Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
InnoCare Pharma Ltd. ( (HK:9969) ) has issued an announcement.
InnoCare Pharma Limited has entered into an exclusive license agreement with Prolium Bioscience Inc. for the development and commercialization of ICP-B02 (CM355), a CD20×CD3 bispecific antibody. This collaboration grants Prolium global rights in non-oncology fields and outside of Asia in oncology fields, while future revenues and milestone payments will be split between Beijing InnoCare and Chengdu Keymed. The agreement is expected to enhance InnoCare’s market positioning by securing significant upfront and potential milestone payments, along with royalties from future sales, highlighting the promising potential of ICP-B02 in both oncology and non-oncology applications.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company focused on innovative therapies in the field of oncology and autoimmune diseases. The company develops and commercializes novel treatments, with a particular emphasis on bispecific antibodies for cancer therapy.
YTD Price Performance: -10.95%
Average Trading Volume: 4,604,930
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$8.15B
For detailed information about 9969 stock, go to TipRanks’ Stock Analysis page.
